Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Spero Therapeutics, Inc. (“Spero” or the “Company”) (NASDAQ: SPRO) and certain...
-
NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abbott Laboratories (“Abbott” or the “Company”) (NYSE: ABT). Such investors are advised to...
-
NEW YORK, May 25, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Axsome Therapeutics, Inc. (“Axsome” or the “Company”) (NASDAQ: AXSM) and certain...
-
NEW YORK, May 25, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Lyft, Inc. (“Lyft” or the “Company”) (NASDAQ: LYFT). Such investors are advised to contact...
-
NEW YORK, May 25, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Okta, Inc. (“Okta” or the “Company”) (NASDAQ: OKTA) and certain of its officers....
-
NEW YORK, May 25, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Enservco Corporation (“Enservco” or the “Company”) (NYSE: ENSV) and certain of...
-
NEW YORK, May 25, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Amgen Inc. (“Amgen” or the “Company”) (NASDAQ: AMGN). Such investors are advised to...
-
NEW YORK, May 25, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Palantir Technologies Inc. (“Palantir” or the “Company”) (NYSE: PLTR). Such investors are...
-
NEW YORK, May 25, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HUTCHMED (China) Limited (“Hutchmed” or the “Company”) (NASDAQ: HCM). Such investors are...
-
NEW YORK, May 25, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Vertex Pharmaceuticals Incorporated (“Vertex” or the “Company”) (NASDAQ: VRTX). Such...